KPIs & Operating Metrics(New)

Additions To Property And Equipment Adjusted Income Before Tax Adjusted Income Before Tax By Segment Assets By Segment Breakdown Of Assets Cardiovascular/Metabolism/Other Revenue Cardiovascular/Metabolism/Other Revenue Annual Consumer Revenue Contractual Boligations Cost Of Products Sold Disaggregated Revenue Mix %Disaggregated Revenues Earnings Before Taxes On Income Ebt By Segment Ebt By Segment Annual Ebt Margin By Segment Annual %Employee Statistics Facilites By Region Gross Margin %Gross Profit Immunology Revenue Immunology Revenue Annual Infectious Diseases Revenue Infectious Diseases Revenue Annual Innovative Medicine Revenue Breakdown Annual International Sales By Segment Interventional Solutions Revenue Annual Inventories Long Lived Assets By Region Medical Devices Revenue Medical Devices Revenue Annual Medtech Revenue Breakdown Annual Neurosciences Revenue Neurosciences Revenue Annual Non Gaap Profitability Non Gaap Profitability %Non Gaap Profitability Annual Non Gaap Profitability Annual %Oncology Revenue Oncology Revenue Annual Opex As A % Of Revenue OPEX Segregation Orthopaedics Revenue Annual Pharmaceutical Revenue Breakdown Property And Equipment Segregation Pulmonary Hypertension Revenue Pulmonary Hypertension Revenue Annual Revenue By Product Revenue By Product %Revenue By Region Revenue By Region %Revenue By Region (Annual)Revenue By Region (Annual) %Revenue By Segment Revenue By Segment %Revenue By Segment Annual Revenue By Segment Annual %Square Footage By Region Surgery Revenue Annual Us Sales By Segment Vision Revenue Annual

Balance Sheet

Daily Values

Growth Metrics

Others

Johnson & Johnson (JNJ) Gross Profit (2016 - 2025)

Johnson & Johnson's Gross Profit history spans 17 years, with the latest figure at $16.6 billion for Q4 2025.

For Q4 2025, Gross Profit rose 7.82% year-over-year to $16.6 billion; the TTM value through Dec 2025 reached $63.9 billion, up 4.22%, while the annual FY2025 figure was $63.9 billion, 4.22% up from the prior year.
Gross Profit for Q4 2025 was $16.6 billion at Johnson & Johnson, down from $16.7 billion in the prior quarter.
Across five years, Gross Profit topped out at $16.7 billion in Q3 2025 and bottomed at $13.8 billion in Q2 2022.
The 5-year median for Gross Profit is $15.0 billion (2023), against an average of $15.1 billion.
The largest annual shift saw Gross Profit surged 33.75% in 2021 before it decreased 14.07% in 2022.
A 5-year view of Gross Profit shows it stood at $16.1 billion in 2021, then decreased by 14.07% to $13.8 billion in 2022, then rose by 5.59% to $14.6 billion in 2023, then rose by 5.45% to $15.4 billion in 2024, then rose by 7.82% to $16.6 billion in 2025.
Per Business Quant, the three most recent readings for JNJ's Gross Profit are $16.6 billion (Q4 2025), $16.7 billion (Q3 2025), and $16.1 billion (Q2 2025).